

**Virginia Medicaid**  
**Pharmacy & Therapeutics Committee Meeting**  
**Draft Agenda (Revised 3/19/12)**  
600 East Broad Street – 7<sup>th</sup> Floor Conference Rooms  
Richmond, VA 23219  
April 19, 2012 – 10 AM

**Welcome and Comments**

**Cindi Jones, Agency Director**

**Call to Order**

**Randy Axelrod, MD, Chairman**

**Drug Utilization Review (DUR) Board Report**

**Donna Proffitt, RPh, Pharmacy Manager**

**Provider Synergies Services Update**

**Debbie Moody, RPh, Clinical Manager**

**Approval of Minutes from October 20, 2011 Meeting**

**P&T Committee Members**

**PDL Management**

**P&T Committee Members**

- **Old Business**
  - Evaluation of Ampyra<sup>®</sup> Utilization
  - Evaluation of Cough and Cold Product Utilization in Children
  - Evaluation of Long-term Use of Long Acting Beta Agonist (LABAs) in Children
  - Cialis<sup>®</sup> for BPH - Criteria Review
- **PDL Phase I – New Drug Review (*Therapeutic Class*)**
  - ***Angiotensin Modulators***
    - Eprosartan mesylate 600 mg tablet
  - ***Hepatitis C Agents***
    - Pegasys<sup>®</sup> and Pegasys ProClick<sup>®</sup> Injection
  - ***Lipotropics – Statins***
    - Atorvastatin
    - Amlodipine-atorvastatin
  - ***Proton Pump Inhibitors (PPIs)***
    - Lansoprazole 15 mg capsule
  - ***Second Generation Antihistamines and Combinations***
    - Levocetirizine solution
- **PDL Phase II – Annual Review (*Therapeutic Class*)**
  - ***Analgesics***
    - Barbiturate & Non-salicylate Analgesics (*and combinations*)
    - Narcotics (*includes Long Acting, Short Acting, combinations, and Lozenges*)
    - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (*includes Cox-2 Inhibitors*)
    - Opioid Analgesics & Dependency
    - Topical Agents & Anesthetics
  - ***Antibiotics/Anti-infectives***
    - 2<sup>nd</sup> and 3<sup>rd</sup> Generation Cephalosporins
    - 2<sup>nd</sup> and 3<sup>rd</sup> Generation Quinolones (systemic)
    - Ketolides & Macrolides (Adult and Pediatric)
    - Oral Antifungals
    - Otic Quinolones
    - Topical Antibiotics

- **PDL Phase II – Annual Review (*continued*)**
  - ***Antivirals***
    - Antivirals for the treatment of Herpes or Influenza
    - Topical Antivirals
  - ***Bone Resorption Suppression and Related Agents***
    - Bisphosphonates
    - Calcitonins
    - Others
  - ***Cardiac Medications***
    - Anticoagulants (*includes low molecular weight heparins, Factor XA inhibitors and oral anticoagulants*)
    - Platelet Inhibitors
  - ***Central Nervous System***
    - Antihyperkinesia/CNS Stimulants
    - Antimigraine
    - Non-Ergot Dopamine Receptor Agonists
    - Skeletal Muscle Relaxants
    - Smoking Cessation
  - ***Dermatologic***
    - Acne Agents (*includes Benzoyl Peroxide, Clindamycin, Topical Retinoids & combinations*)
    - Topical Agents For Psoriasis
  - ***Endocrine and Metabolic Agents***
    - Androgenic Agents
    - Antihyperuricemics
    - Contraceptives (*Oral, Vaginal & Transdermal*)
    - Erythropoiesis Stimulating Proteins (*The annual review of this class was deferred to the spring meeting from October 2011. This class will remain in Phase II moving forward. Existing contracts for this drug class will end on June 30, 2012 and new contracts will begin on July 1, 2012.*)
    - Injectable Hypoglycemics (*includes Insulins, Incretin Mimetics, GLP-1 Receptor Agonists*)
    - Oral Hypoglycemics (*includes 2<sup>nd</sup> Generation Sulfonylureas, Alpha-Glucosidase Inhibitors, Biguanides, Biguanide combinations, Meglitinides, Thiazolidinediones, DPP-IV Inhibitors and combinations*)
    - Progestational Agents
    - Vaginal Estrogens
  - ***Gastrointestinal***
    - Motility Agents – GI Stimulants
  - ***Immunologic Agents***
    - Multiple Sclerosis Agents
    - Self Administered Drugs for Rheumatoid Arthritis
  - ***Ophthalmics***
    - Ophthalmic Glaucoma Agents (*includes Alpha-2 Adrenergic, Beta-blockers, Carbonic Anhydrase Inhibitors, Prostaglandin Inhibitors*)
    - Ophthalmic Anti-Inflammatory Agents
    - Ophthalmic Antibiotics (*includes Quinolones & Macrolides*)
    - Allergic Conjunctivitis (*includes Ophthalmic Antihistamines & Mast Cell Stabilizers*)

- **PDL Phase II – Annual Review (*continued*)**
  - **Respiratory**
    - Cough & Cold (*includes 1st Generation Antihistamines, Antihistamines & Expectorant combination, Expectorants, Narcotic Antitussive & Decongestant combinations, Narcotic Antitussive & Expectorant combinations, Non-narcotic Antitussive & Decongestant combinations, Non-narcotic Antitussive, 1st Generation Antihistamine & Decongestant combinations*)
    - Leukotriene Formation Inhibitors and Modifiers

**Confidential Meeting (Pricing Information Discussion)**

**P&T Committee Members & DMAS Staff**

**Criteria Discussion of Phase I New Drugs**

**P&T Committee Members**

**Criteria Discussion of Phase II New Drugs**

**P&T Committee Members**

**Next Meet – October 18, 2012 (tentative)**

**Randy Axelrod, MD, Chairman**

**Oral Presentations:** The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on *only* the drug classes in Phase II which are scheduled for review at the October meeting and new drugs in PDL Phase I listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase II Annual Review – April 2011 to present
- New Drugs in PDL Phase I Drug Classes – April 2010 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to [pdlinput@dmass.virginia.gov](mailto:pdlinput@dmass.virginia.gov) and [dfmoody@magellanhealth.com](mailto:dfmoody@magellanhealth.com) by 5 p.m. EST on **Friday, March 23, 2012.**